Evidence map›Paper›PMID 42850488›Full record

ReviewJournal of cardiovascular translational research2026

YAP and WWTR1/TAZ Connect Mechanotransduction and Mitochondrial Metabolism in Cardiac Hypertrophy and Ventricular Remodeling.

Feihu Yu, Zuqiu Liu, Jimiao Qiu, Huashan Chen, Xiaowei Song, Songqun Huang, Changjin Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of cardiovascular translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Feihu Yu *Department of Cardiovascular Medicine, The 906th Hospital of the PLA Joint Logistics Support Force, Ningbo, Zhejiang, 315000, China.
Zuqiu Liu *Department of Cardiovascular Medicine, The 906th Hospital of the PLA Joint Logistics Support Force, Ningbo, Zhejiang, 315000, China.
Jimiao Qiu *Department of Cardiovascular Medicine, The 906th Hospital of the PLA Joint Logistics Support Force, Ningbo, Zhejiang, 315000, China.
Huashan ChenDepartment of Cardiovascular Medicine, The 906th Hospital of the PLA Joint Logistics Support Force, Ningbo, Zhejiang, 315000, China.
Xiaowei SongDepartment of Cardiovascular Medicine, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Songqun HuangDepartment of Cardiovascular Medicine, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Changjin LiDepartment of Cardiovascular Medicine, The 906th Hospital of the PLA Joint Logistics Support Force, Ningbo, Zhejiang, 315000, China. asd123carl@sina.com.ORCID http://orcid.org/0000-0002-4430-5450

Funding

Zhejiang Provincial Natural Science Foundation of China LQN25H020019
6 · The paper itself

Abstract

Cardiac hypertrophy is a mechanometabolic remodeling process shaped by mechanical load, matrix stiffness and mitochondrial adaptation. YAP and TAZ, encoded by YAP1 and WWTR1, are paralogous, non-DNA-binding transcriptional co-activators that link cytoskeletal tension to TEAD-dependent transcription. This review organizes current evidence along a mechanical stress-YAP/TAZ activation-mitochondrial remodeling-ventricular remodeling axis and distinguishes direct human myocardial data, animal cardiac mechanisms, related cardiovascular or in vitro evidence, and cross-disease extrapolation. Experimental studies suggest that TEAD1 supports mitochondrial gene programs, transient YAP activation promotes glycolytic compensation during early pressure overload, whereas sustained Yap1 activation may impair mitochondrial biogenesis. Cell-specific studies further implicate fibroblast, endothelial, immune and epicardial programs, although many data derive from non-hypertrophic contexts. Thus, the adaptive-to-maladaptive YAP/TAZ model remains provisional. Human lineage-resolved data are limited, and no YAP/TAZ-targeted therapy is established for cardiac hypertrophy.

Indexed as

Adaptor Proteins, Signal TransducingCardiomegalyEnergy MetabolismIntracellular Signaling Peptides and ProteinsMechanotransduction, CellularMitochondria, HeartMyocardiumTranscription FactorsVentricular RemodelingAnimalsHumansMetabolic ReprogrammingTrans-ActivatorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingIntracellular Signaling Peptides and ProteinsTrans-ActivatorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsWWTR1 protein, humanYAP1 protein, humanYAP-Signaling ProteinsCardiac fibrosisCardiac hypertrophyHeart failureMechanotransductionMitochondrial metabolismMitochondrial quality controlWWTR1YAP/TAZ

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.